Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
10.27
-0.06 (-0.58%)
At close: Mar 6, 2026, 4:00 PM EST
10.31
+0.04 (0.39%)
After-hours: Mar 6, 2026, 7:50 PM EST
Ocular Therapeutix Employees
Ocular Therapeutix had 325 employees as of December 31, 2025. The number of employees increased by 51 or 18.61% compared to the previous year.
Employees
325
Change (1Y)
51
Growth (1Y)
18.61%
Revenue / Employee
$159,849
Profits / Employee
-$818,274
Market Cap
2.24B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Ultragenyx Pharmaceutical | 1,371 |
| Adaptive Biotechnologies | 624 |
| Ascentage Pharma Group International | 605 |
| Galapagos NV | 558 |
| Immunome | 168 |
| Disc Medicine | 155 |
| Tango Therapeutics | 155 |
OCUL News
- 4 days ago - Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript - Seeking Alpha
- 16 days ago - Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 17 days ago - Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript - Seeking Alpha
- 18 days ago - Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial - Reuters
- 21 days ago - Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - GlobeNewsWire
- 4 weeks ago - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive - Seeking Alpha
- 3 months ago - Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug - Benzinga